Details
Description: Mouse monoclonal antibody to human Leukemia inhibitory factor (LIF).
Purification: Protein G affinity purified
Product Type: Primary antibody
Target Protein: LIF
Immunogen: Recombinant LIF
Fusion Myeloma: Sp2/0-Ag14
Specificity: This antibody is reactive to recombinant human LIF protein.
Species Reacitvity: Human, others not tested
Host / Isotype: Mouse, IgG1 Kappa
Formulation: Lyophilized from a solution in 0.01M PBS, pH 7.0
Reconstitution: Double distillated water is recommended to adjust the final concentration to 1mg/mL.
Storage: Store at -20oC
Research Area: Cytokine and oncology
Background:
LIF is a cytokine with important functions in diversified biological processes including cell differentiation, inflammatory response, neuronal development and cancer progression. LIF can induce the terminal differentiation of leukemia cells, thus it inhibits the further progression of leukemia. However, it has opposite effects on many other cancers, such as breast cancer and bladder cancer etc. Several recent studies have shown that LIF might play a significant role in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis development. Treatment of pancreatic cancer by blocking LIF is currently under investigation. Research also demonstrated that elevated LIF level in pancreatic tissue and circulation was correlated with the cancer progression, indicating that LIF might be useful as a biomarker.
Application:
Western blot: LIF mAb clone 10B5 detected recombinant LIF protein on Western Blot. The antibody can detect less than 10ng/well of recombinant LIF on the blot.
Immunohistochemistry (IHC): LIF mAb clone 10B5 was used to stain pancreatic cancer tissue and paracancerous tissue.
Briefly, the paraffin sections of pancreatic cancer tissue and paracancerous tissue were treated with EDTA to re-naturalize antigen epitopes and treated with 3% H2O2 to remove endogenous catalase. The sections were blocked with goat serum, incubated with 1:500 diluted LIF mAb 10B5 overnight at 4oC and washed, followed by incubation with HRP-conjugated goat anti-mouse IgG. Sections were stained with DAB and counter-stained with Hematoxylin.
Indirect EIA: LIF mAb clone 10B5 is reactive to recombinant human LIF in indirect ELISA.
References:
Xuetian Yue et al., The regulation of leukemia inhibitory factor. Cancer Cell Microenvironment 2015; 2(3): e877.
Yu Shi et al., Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature 2019 569 (131–135),
Christian Bressy et al., LIF drives neural remodeling in pancreatic cancer and offers a New Candidate Biomarker 2018 15:78(4):909-921
If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.
